TCGA-A2-A1FV-01A-11R-A13Q-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 24
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.400
- UV_RESPONSE_DN+0.360
- TGF_BETA_SIGNALING+0.300
- HEDGEHOG_SIGNALING+0.150
- MYC_TARGETS_V1+0.140
- PROTEIN_SECRETION+0.130
- HEME_METABOLISM+0.060
- SPERMATOGENESIS+0.060
- WNT_BETA_CATENIN_SIGNALING+0.040
- MITOTIC_SPINDLE+0.010
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.680
- INTERFERON_GAMMA_RESPONSE-0.570
- ALLOGRAFT_REJECTION-0.530
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.470
- IL6_JAK_STAT3_SIGNALING-0.420
- INFLAMMATORY_RESPONSE-0.410
- GLYCOLYSIS-0.390
- COMPLEMENT-0.360
- P53_PATHWAY-0.340
- CHOLESTEROL_HOMEOSTASIS-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A8-A091-01A-11R-A00Z-07 | — | B | 0.864 |
| 2 | SRR8942973 | — | — | 0.852 |
| 3 | SJEPD030911_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.848 |
| 4 | TCGA-A7-A0D9-01A-31R-A056-07 | — | B | 0.843 |
| 5 | TCGA-A7-A0DC-01A-11R-A00Z-07 | — | D | 0.839 |
| 6 | TCGA-OR-A5L8-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.837 |
| 7 | SRR8518450 | — | A | 0.836 |
| 8 | SRR8942980 | — | — | 0.835 |
| 9 | SRR12202470 | — | — | 0.833 |
| 10 | SRR8613756 | — | E | 0.832 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.400 | Cobimetinib | — uncovered |
| UV_RESPONSE_DN | 0.360 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.300 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.150 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.140 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.130 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.060 | Temsirolimus | — uncovered |
| SPERMATOGENESIS | 0.060 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.040 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.010 | Inavolisib | — uncovered |